TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01425203
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ribavirin (weight-based dosing) 800 to 1400 mg/day PO divided twice daily dose (BID).
Study: NCT00649532
Drug: Ondansetron Tablets 24 mg
Normalized name: ondansetron Oral Tablet
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24mg, single dose fasting
Study: NCT00264875
Drug: pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 75mg BID, titrated up to 300mg according to individual response and tolerability
Study: NCT01456676
Drug: Nilotinib + LDE225
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib is an aminopyrimidine ATP-competitive inhibitor of the protein tyrosine kinaseactivity of BCR-ABL.
Study: NCT01322139
Drug: Placebo spray and oral moxifloxacin placebo
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
Study: NCT00283595
Drug: Recombinant Human Growth Hormone
Normalized name: Recombinant human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage increased in steps for first four weeks. Self injection qd x 12 weeks
Study: NCT00845728
Drug: Indacaterol 150 µg
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol 150 µg o.d. delivered via SDDPI
Study: NCT00845728
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 µg o.d. delivered via handihaler®
Study: NCT00290433
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycle 1: 600 mg/m\^2 by vein Continuous Infusion Over Days 1, 2, and 3.
Study: NCT00290433
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycle 1: 1.4 mg/m\^2 by vein On Day 4 and 11.
Study: NCT00290433
Drug: Ara-C
Normalized name: Ara-C
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cycle 1 and 2: 3 Gm/m\^2 Over 2 Hours Twice Daily On Days 2 and 3.
Study: NCT00290433
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cycle 1: 40 mg by vein or by mouth daily on Days 1-4 and 11-14.
Study: NCT00290433
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cycle 1 and 2: 300 or 480 mcg subcutaneously 24 hours after end of Day 4 vincristine.
Study: NCT00290433
Drug: Doxil
Normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycle 1: 25 mg/m\^2 by vein Over 1 Hour on Day 2.
Study: NCT01019421
Drug: Lu AE58054
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on treatment to donepezil
Study: NCT01322139
Drug: Sativex spray and oral moxifloxacin placebo
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 Sativex sprays (4 sprays twice daily every 12 hours) + 16 or 28 placebo sprays (8 or 14 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
Study: NCT01322139
Drug: Sativex spray and oral moxifloxacin placebo
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 or 36 Sativex sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
Study: NCT01322139
Drug: Placebo spray and moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin 400 mg tablet on Day 5.
Study: NCT00980382
Drug: S-1, Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Phase I study~  * S-1 (level 0, 1/2, 3/4, 5: 60, 70, 80, 90 mg/m2/day) q 12 hours po Days 1-14~ * Docetaxel (level 0/1,2/3, 4/5: 25, 30, 35 mg/m2) iv : Days 1, 8~* Phase II study~  * S-1 (80mg/m2/day) q 12 hours po Days 1-14~ * Docetaxel (35 mg/m2) iv : Days 1, 8
Study: NCT01702610
Drug: Temozolomide and Accelerated Hypofractionation RT
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02575521
Drug: Propofol-Dexmedetomidine group
Normalized name: Propofol
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Porofol (1.5-2 mg/kg/h) infusion, Dexmedetomidine (0.2-1µg/kg/h) infusion and Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value). Maintenance infusions will start immediately after induction.
Study: NCT02575521
Drug: Sevoflurane group
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane at a concentration of 2-2.5%., Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value).
Study: NCT02117765
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03662425
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It's a two-week treatment trial.Subjects self-administer intranasal study drug twice daily; before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of OT spray containing approximately 24 international units of OT
Study: NCT03662425
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It's a two-week treatment trial. Subjects self-administer intranasal study drug twice daily; before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of saline spray containing approximately 24 international units of saline
Study: NCT02139826
Drug: IX-01
Normalized name: Hematoporphyrin ix
DrugBank: Hemoporfin (DB16183)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02537457
Drug: Rivaroxaban (BAY 59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban granule15mg for one day
Study: NCT02537457
Drug: Rivaroxaban (Xarelto, BAY 59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban tablet15mg for one day
Study: NCT04624243
Drug: MK-8189
Normalized name: MK-8189
DrugBank: MK-8189 (DB19153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8189 administered QD at a dose of 8 mg, 16 mg, or 24 mg via oral tablet.
Study: NCT00701675
Drug: sertraline 50 mg daily
Normalized name: sertraline 50 MG
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg daily
Study: NCT00701675
Drug: sertraline 100 mg daily
Normalized name: sertraline 100 MG
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg daily
Study: NCT03237065
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (Injectafer®; 50 mg/mL) was the comparator in this trial. The dose of ferric carboxymaltose for the individual subject was 750 mg, infused over at least 15 minutes at baseline and on day 7 (cumulative dose: 1500 mg).
Study: NCT01660932
Drug: omega
Normalized name: Omega-3
DrugBank: N-omega-propyl-L-arginine (DB02644)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04624243
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone administered QD at a dose of 6 mg via oral capsule.
Study: NCT04624243
Drug: Placebo to MK-8189
Normalized name: MK-8189
DrugBank: MK-8189 (DB19153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8189-matching placebo administered QD via oral tablet.
Study: NCT04624243
Drug: Placebo to risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone-matching placebo administered QD via oral capsule.
Study: NCT01200901
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: quetiapine XR 100 - 300 mg (flexible dosing)
Study: NCT01356914
Drug: BMS-914392
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 10 mg, Every Day (QD), 20 days
Study: NCT01356914
Drug: BMS-914392
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 10 mg, Three Times Daily (TID), 20 days
Study: NCT01356914
Drug: BMS-914392
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 20 mg, Three Times Daily (TID), 20 days
Study: NCT02963324
Drug: Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03126149
Drug: PF-06667272
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose of PF-06667272
Study: NCT01323218
Drug: 25 OH vitamin D
Normalized name: 1α,25(OH)2D3
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After written informed consent, patients will be randomized to receive a single dose of oral vitamin D (400 000 UI) or placebo. Subjects will undergo medical screening before randomisation into placebo or active group. Follow-up measurements will be performed at the beginning (day 0) and after 32 days of vitamin D supplementation: clinical examination, biological check up and sleep parameter evaluation. Patients will be instructed to stop using continuous positive airway pressure device for two nights before nocturnal sleep studies
Study: NCT00699296
Drug: Panobinostat (LBH589)
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 20mg/day p.o. on three times-a- week
Study: NCT03053362
Drug: Vortioxetine
Normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Observing change in cognition using THINC-it tool in patients with MDD.
Study: NCT04146610
Drug: an antibody drug conjugate
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple dose grouping
Study: NCT04304209
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130mg/m2, d1 q3w, in Capeox regimen (100mg/m2 when used cocurrently with radiotherapy), intravenous infusion
Study: NCT04304209
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg, d1 q3w, intravenous infusion
Study: NCT03681470
Drug: Aczone Gel
Normalized name: dapsone Topical Gel [Aczone]
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aczone Gel 7.5%
Study: NCT02510287
Drug: Bupivacaine and Fentanyl Initial Dose
Normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution)
Study: NCT02510287
Drug: Bupivacaine and Fentanyl: Continuous Epidural Infusion
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12 ml / hour)
Study: NCT02510287
Drug: Bupivacaine and Fentanyl: Programmed Intermittent Epidural Bolus
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12ml) bolus will be administered each hour at a rate of 500ml/hour
Study: NCT02510287
Drug: Rescue Bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.
Study: NCT02510287
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered.
Study: NCT00432432
Drug: Infliximab and MTX
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: MTX 15mg weekly Infliximab 5mg/kg given at day 0, wk 2, wk6
Study: NCT04176523
Drug: Carglumic Acid
Normalized name: Carglumic Acid
DrugBank: Carglumic acid (DB06775)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maintenance therapy with carglumic acid
Study: NCT01744197
Drug: Synera (lidocaine 70mg/tetracaine 70mg)
Normalized name: lidocaine 70 MG / tetracaine 70 MG [Synera]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will receive 2 patch applications during this study: one Synera, one placebo. The 2 patch applications must be done on separate days. Only 1 patch will be used per application. Arm 1 subjects will receive Synera patch for the 1st application, and placebo for the second. Arm 2 patients will receive placebo patch for the 1st application, and Synera patch for the second.
Study: NCT00216632
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02174250
Drug: Istradefylline 40 mg
Normalized name: istradefylline 40 MG
DrugBank: Istradefylline (DB11757)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On Day 1, istradefylline 1 × 40-mg tablet administered alone
Study: NCT02174250
Drug: Rifampin 300mg BID + istradefylline 40mg Day 8 only
Normalized name: istradefylline 40 MG
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Days 1 - 20, rifampin 300mg BID; On Day 8, istradefylline 40 mg administered first with rifampin about 2 hours after istradefylline administration
Study: NCT02967029
Drug: Esmolol Hydrochloride
Normalized name: Esmolol Hydrochloride
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the influence of brevibloc as a hypotensive agent on rSO2
Study: NCT00690898
Drug: Lanreotide autogel 120 mg
Normalized name: lanreotide
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12 months
Study: NCT03612232
Drug: Cabozantinib-s-malate
Normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral cabozantinib-S-malate 60 mg as a daily single oral dose continuously
Study: NCT03299829
Drug: Trientine
Normalized name: Trientine
DrugBank: Triethylenetetramine (DB06824)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Trientine is a chelating agent for removing the copper from the body
Study: NCT00458211
Drug: ziprasidone
Normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ziprasidone by mouth 40mg twice a day (bid) for one day, then 80mg bid; may be increased to 120mg bid after three weeks
Study: NCT01965301
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single oral dose of Diphenhydramine 50mg
Study: NCT04155554
Drug: Bictegravir/emtricitabine/tenofovir alafenamide
Normalized name: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Switch patients from dolutegravir/lamivudine/abacavir to bictegravir/emtricitabine/tenefovir alafenamide to study neuropsychiatric side effects and neurocognitive function
Study: NCT04155554
Drug: Dolutegravir/lamivudine/abacavir
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continuing dolutegravir/lamivudine/abacavir to study neuropsychiatric side effects and neurocognitive function
Study: NCT00052689
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00052689
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01695902
Drug: Levosert-20
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01695902
Drug: Mirena
Normalized name: Mirena
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01814514
Drug: Timolol-trusopt
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02929264
Drug: ABX-1431
Normalized name: ABX-1431
DrugBank: ABX-1431 (DB16036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, 40 mg, single dose
Study: NCT02825095
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
DrugBank: Benzoic acid (DB03793)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inserting a chest drain will be after local anesthesia with 10-20 mL of Lidocaine hydrochloride 20MG/ML - Esracain injection 2%
Study: NCT02020486
Drug: Perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg up to 4 mg
Study: NCT02020486
Drug: Perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg up to 6 mg
Study: NCT00419328
Drug: NGR-hTNF
Normalized name: NGR-hTNF
DrugBank: Tengonermin (DB16689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: NGR-hTNF~NGR-hTNF was administered every 3 weeks by a 1 hour intravenous iv infusion. NGR-hTNF in PBS was diluted in 0.9% NaCl, containing human serum albumin.~Step 1:~* starting dose: 0.2 μg/m2~* following doses: 0.4, 0.8 and 1.6 μg/m2.~* number of patients: 4 per dose level~Step 2:~* starting dose: 3.2 μg/m2~* following doses: 6.4 and 12.8 μg/m2~* number of patients: 3 per dose level~Step 3:~* starting dose: 19.2 μg/m2~* following doses: 28.8, 43.2 and 64.8 μg/m2~* number of patients: 3 per dose level~Step 4:~* starting dose: 86.2 μg/m2~* following doses: 114.6 and 152.4 μg/m2~* number of patients: 3 per dose level
Study: NCT02876887
Drug: Cocoa
Normalized name: COCOA
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02361931
Drug: A hydrogel containing erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of wound care, which includes initial debridement, wound cleansing, pressure relief, and infection control. RMD-G1 applied daily onto a clean wound at 0.25g per sq.cm. of wound surface. After its application, the wound is covered with a dressing in order to prevent leakage of the gel and contamination of the wound area.
Study: NCT02361931
Drug: Hydrogel (as a part of SOC)
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of wound care, which includes initial debridement, wound cleansing, pressure relief, and infection control. Hydrogel applied daily onto a clean wound at 0.25g per sq.cm. of wound surface. After its application, the wound is covered with a dressing in order to prevent leakage of the gel and contamination of the wound area.
Study: NCT04668859
Drug: Midodrine
Normalized name: Midodrine
DrugBank: Midodrine (DB00211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vasoactive that is metabolized by the liver an peripheral tissues into desglymidodrine, an active metabolite. It produces arteriolar and venous constriction with a subsequent elevation in blood pressure.
Study: NCT04668859
Drug: Methylcellulose
Normalized name: Methylcellulose
DrugBank: Methylcellulose (DB11228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will consist of inert methylcellulose
Study: NCT02144012
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For the first three-week cycle, trastuzumab was administered IV at 8 mg/kg. For subsequent cycles, trastuzumab was administered IV at 6 mg/kg Q3W.
Study: NCT02144012
Drug: Trastuzumab Emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab emtansine 3.6 milligrams/kilogram (mg/kg) was administered intravenously (IV) over 30-90 minutes Q3W.
Study: NCT02144012
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel was administered IV at either 75 milligrams/square meter (mg/m\^2) or 100 mg/m\^2 Q3W.
Study: NCT01058096
Drug: Cariprazine
Normalized name: Cariprazine
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine.
Study: NCT00236977
Drug: Venofer
Normalized name: Venofer
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iron sucrose injection; 500 mg intravenous (IV) infusion administered over 3.5-4 hours on Days 0 and 14, or 200 mg injections administered over 2-5 minutes on 5 different occasions from Day 0 to Day 14.
Study: NCT00236977
Drug: Ferrous Sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral iron tablets; 325 mg three times a day orally for 56 days
Study: NCT02870361
Drug: intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01849003
Drug: GS-6615
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-6615 tablet(s) administered orally
Study: NCT02613598
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02613598
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00835081
Drug: Cefadroxil 500 mg Capsules
Normalized name: Cefadroxil
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 500 mg
Study: NCT00835081
Drug: DURICEF® capsules 500 mg
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 500 mg
Study: NCT01412515
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: everolimus per os 10mg per day
Study: NCT01367054
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg tablet
Study: NCT00501735
Drug: Forodesine 200 mg
Normalized name: Forodesine
DrugBank: Forodesine (DB06185)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 2 x 100mg tablets once daily
Study: NCT02744287
Drug: Rimiducid
Normalized name: Rimiducid
DrugBank: Rimiducid (DB04974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimerizer infusion to activate the iMC of the BPX-601 cells for improved proliferation and persistence